The estimated Net Worth of Federico Grossi is at least $8.36 Million dollars as of 5 January 2023. Mr. Grossi owns over 2,500 units of Apellis Pharmaceuticals Inc stock worth over $3,639,750 and over the last 5 years he sold APLS stock worth over $1,959,602. In addition, he makes $2,759,480 as Chief Medical Officer at Apellis Pharmaceuticals Inc.
Sign up
Mr. Grossi APLS stock SEC Form 4 insiders trading
Federico has made over 50 trades of the Apellis Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of APLS stock worth $121,975 on 5 January 2023.
The largest trade he's ever made was exercising 15,000 units of Apellis Pharmaceuticals Inc stock on 25 January 2021 worth over $54,450. On average, Federico trades about 1,950 units every 17 days since 2020. As of 5 January 2023 he still owns at least 94,884 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Mr. Grossi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Federico Grossi biography
Federico Grossi M.D. Ph.D., is Chief Medical Officer of the Company. Dr. Grossi has served as our Chief Medical Officer since April 2019, having served as our Executive Vice President of Clinical Development from October 2017 until April 2019, our Vice President of Clinical Development from October 2014 to October 2017 and as our Clinical Research Director from April 2010 to June 2012. Dr. Grossi served as Executive Vice President of Potentia from October 2013 to September 2014, and as Clinical Research Director of Potentia from 2006 to April 2010. From June 2012 to October 2014, Dr. Grossi worked as an independent early stage clinical research consultant. Dr. Grossi received his M.D. from the University of Córdoba in Argentina and his Ph.D. in physiology from the University of Louisville. Following his post-graduate training in surgery, where he developed his expertise in microsurgery and composite tissue transplantation, Dr. Grossi joined the Plastic Surgery Research Laboratory at the University of Louisville.
What is the salary of Federico Grossi?
As the Chief Medical Officer of Apellis Pharmaceuticals Inc, the total compensation of Federico Grossi at Apellis Pharmaceuticals Inc is $2,759,480. There are 2 executives at Apellis Pharmaceuticals Inc getting paid more, with Cedric Francois having the highest compensation of $4,267,180.
How old is Federico Grossi?
Federico Grossi is 45, he's been the Chief Medical Officer of Apellis Pharmaceuticals Inc since 2019. There are 20 older and 3 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
What's Federico Grossi's mailing address?
Federico's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., , WALTHAM, MA, 02451.
Insiders trading at Apellis Pharmaceuticals Inc
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, and Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
What does Apellis Pharmaceuticals Inc do?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
What does Apellis Pharmaceuticals Inc's logo look like?
Complete history of Mr. Grossi stock trades at Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc executives and stock owners
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Cedric Francois,
President, Chief Executive Officer, Co-Founder, Director -
Lukas Scheibler,
Chief Innovation Officer -
Federico Grossi,
Chief Medical Officer -
Thomas Lackner,
Senior Vice President, Head of Europe -
Pascal Deschatelets,
Co-Founder, Chief Operating Officer -
Timothy Sullivan,
Chief Financial Officer, Treasurer -
Dr. Cedric Francois,
Co-Founder, Pres, CEO & Director -
Timothy E. Sullivan,
Chief Financial Officer -
Dr. Pascal Deschatelets Ph.D.,
Co-Founder & Chief Scientific Officer -
Adam J. Townsend,
Chief Commercial Officer -
Gerald Chan,
Independent Chairman of the Board -
Stephanie O'Brien,
Independent Director -
Alec Machiels,
Independent Director -
A. Sinclair Dunlop,
Independent Director -
Alec Machiels J.D., MBA,
Co-Founder & Independent Director -
Sam Martin,
IR Contact Officer -
Paul Fonteyne,
Independent Director -
Adam Townsend,
Chief Commercial Officer -
David Watson,
General Counsel, Vice President of Corporate Development -
Nicole Perry,
Vice President - Finance -
Victoria Brown,
Senior Vice President, Program Team Lead – Systemic Chronic -
David O. Watson,
Gen. Counsel -
Meredith Kaya,
Sr. VP, Investor Relations & Strategic Fin. -
James G. Chopas CPA,
VP, Corp. Controller & Chief Accounting Officer -
Dr. Lukas Scheibler M.D., Ph.D.,
Chief Innovation Officer -
Karen Lewis,
Chief People Officer -
Nur Nicholson,
Chief Technical Operations Officer -
Dr. Federico Grossi M.D., Ph.D.,
Co-Founder & Chief Medical Officer -
Nur Nicholson,
Chief Technical Officer -
Karen Lewis,
Chief People Officer -
Venture Investments Ltd Mor...,
10% owner -
Lucia Celona,
See Remarks -
Ahmad Sadr,
See Remarks -
Jeffrey Eisele,
Chief Development Officer -
Mark Jeffrey De Long,
Chief Business & Strat Officer -
James George Chopas,
VP/Chief Accounting Officer -
Caroline Baumal,
Chief Medical Officer